{"brief_title": "Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma", "brief_summary": "The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.", "condition": "Non-Hodgkin's Lymphoma", "intervention_type": "Drug", "intervention_name": "Motexafin gadolinium", "criteria": "Inclusion Criteria: - \u2265 18 years old - Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (MALT) types - Failed \u2265 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy - ECOG performance status score either 0 or 1 - Willing and able to provide written informed consent Exclusion Criteria: Laboratory values of: - Platelet count < 50,000/\u00b5L - AST or ALT > 2 x the upper limit of normal (ULN) - Total bilirubin > 2 x ULN - Creatinine > 2.0 mg/dL and - Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression) - Uncontrolled hypertension - Known history of porphyria, G6PD deficiency, HIV", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00086034.xml"}